Background Evidence for the relationship between antidepressant use during pregnancy and the risk of attention-deficit/ hyperactivity disorder (ADHD) in the children is conflicting.
Introduction
Depression during pregnancy is common, with an estimated prevalence of 20% worldwide. 1 The rate of antidepressant prescriptions for pregnant women has risen over the past decade, and current estimates suggest that at least one in ten women use antidepressants during pregnancy. [2] [3] [4] Although antidepressants may partially relieve the threat of antenatal depression to maternal and neonatal health, concerns about the safety of antidepressant use during pregnancy are emerging. 5 Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous neurodevelopmental disorder characterised by impaired attention, hyperactivity, and lack of impulse control. 6 The prevalence of ADHD varies worldwide with estimates ranging from 2.6 to 4.5% in children and adolescents. 7 ADHD is highly heritable 8 ; however, accumulating evidence suggests that environmental factors are also involved in the development of this disorder. 9 Thus, recognition of the risk factors for ADHD and implementation of appropriate interventions may help to prevent the disorder.
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Antidepressant use during pregnancy is a risk factor for ADHD, given that the long-lasting effects of in utero exposure to antidepressants on brain function and behaviour are well established. 10 Several epidemiological case-control studies [11] [12] [13] have investigated the association between prenatal exposure to antidepressants and the risk of ADHD, but the results have been inconsistent. Given that the various factors associated with prenatal exposure to antidepressants (i.e. type of antidepressant, time of exposure, and maternal psychiatric status) may differentially affect the risk of ADHD, it is reasonable to analyse these factors separately (Table 1) .
Although several systematic reviews have investigated the effects of gestational antidepressant use on various neurodevelopmental disorders, 10, 14, 15 to our knowledge, no previous review has investigated the effects on ADHD alone. Given the widespread use of antidepressants during pregnancy, it is important to determine whether there is a relation between antidepressant use and the risk of ADHD in children. We conducted a systematic literature review and meta-analysis to assess the association between fetal exposure to antidepressant drugs and the subsequent development of ADHD.
Methods

Search strategy
We followed the guidelines developed by the Meta-analysis of Observational Studies in Epidemiology Group for our meta-analysis. 16 We conducted a comprehensive search of the PubMed, EMBASE, PsycINFO, and CINAHL databases up to October 2017 for peer-reviewed studies. Synonymous terms (including MeSH terms) were used to develop the search strategy (Appendix S1). Additionally, reference lists of the retrieved articles were hand-searched for further relevant articles.
Study selection
Observational studies examining the association between antidepressant use during pregnancy and the risk of ADHD in offspring were included in our meta-analysis. A study was considered eligible if it: (1) used a cohort study design, (2) included an unexposed reference group, and (3) reported either a risk ratio (RR) or hazard ratio (HR). We excluded case-control studies, case reports and series, animal studies, editorials, and reviews.
Data extraction and quality assessment Data were extracted independently by H.Y.J. and C.T.P., and discrepancies were resolved by a third author before the final analysis. The data obtained from each study included: author, year of publication, data source, study time/period, study design, number of participants, outcome assessment, ascertainment of antidepressant exposure, statistical adjustments, and quality. Study-specific RRs and HRs with 95% confidence intervals (CIs) are shown in Table S1 . As recommended by the Cochrane Collaboration, the methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). Table S1 .
Data analysis
Statistical analyses were conducted using STATA 10.0 software (StataCorp LP, College Station, TX, USA). The risk of ADHD was expressed as RR or HR (95% CIs) in the cohort studies. The I 2 statistic was used to assess heterogeneity among studies, where an I 2 estimate >50% was considered to indicate significant heterogeneity. 18 A random-effect model was used to calculate summary hazard risks of ADHD with 95% CIs, accounting for between study variance. 19 We chose this model because of anticipated significant heterogeneity between studies in terms of population and methods used to ascertain outcomes. A fixed effects model was used to obtain overall combined estimates for ADHD risk for studies that reported separately based on time of exposure, type of antidepressant, and different comparison groups. We also conducted a sensitivity analysis using a fixed effect model to investigate the influences of single studies on the overall risk estimate by omitting one study in each turn. Publication bias was not assessed because fewer than 10 studies were included in the meta-analysis. 20 
Results
The studies selected and excluded from the meta-analysis are shown in Figure S1 . Using keywords, we identified 295 potentially eligible articles in the database searches. Of these, 23 citations were retrieved for full-text review. After full-text screening, six cohort studies, [21] [22] [23] [24] [25] [26] four conducted in Europe, [21] [22] [23] one in Canada, 24 and one in China, 25 met our inclusion criteria. All of the studies investigated prenatal antidepressant exposure; however, Sunjuan et al. 26 assessed antidepressant exposure during the first trimester only. Only one study used both a prescription database and maternal self-report to verify antidepressant use during pregnancy. Available regional disease registries were used to identify ADHD cases in all of the studies with the exception of that conducted by Grzeskowiak et al., 22 which used the parent-report version of the Strengths and Difficulties Questionnaire. Study-specific and population characteristics are shown in Table S2 .
Based on the methodological quality assessment scores, all studies were of high quality and the mean score of the six studies was 8.2. The score breakdown is shown in Table S3 .
Assessment of the association between antidepressant exposure during pregnancy and risk of ADHD in children
The meta-analysis of the six cohort studies revealed a significant relation between antidepressant exposure during pregnancy and the risk of ADHD (HR 1.34, 95% CI 1.14-1.57, P < 0.001; Figure 1) ; however, we found considerable heterogeneity across the studies (I 2 = 79.1%). The sensitivity analyses showed no substantial change in pooled risk estimates upon exclusion of any single study; the pooled HRs for ADHD ranged from 1.25 to 1.37.
Outcomes were assessed according to the trimester of pregnancy in four studies 21, [24] [25] [26] ( Figure S2 ). The meta-analysis revealed that the association between ADHD risk and gestational antidepressant exposure was significant whether exposure occurred during the first trimester (HR 1.39; 95% CI 1.30-1.48; I 2 = 91%) or the second and third trimesters (HR 1.37; 95% CI 1.18-1.60; I 2 = 0%). Five studies 21, [23] [24] [25] [26] were eligible for the analysis of antidepressant drug type ( Figure S3 ). We found that the use of selective serotonin re-uptake inhibitors (SSRIs) during pregnancy was significantly associated with an increased risk of ADHD in offspring (HR 1.50; 95% CI 1.39-1.61; I 2 = 67%). Similarly, a meta-analysis of three studies 21, 24, 25 found a significant association between non-SSRI antidepressant use and the risk of ADHD (HR 1.49; 95% CI 1.22-1.82; I 2 = 0%).
Assessment of preconception antidepressant use and the risk of ADHD in children
Three studies 23, 25, 26 were eligible for the analysis of antidepressant use before pregnancy and the risk of ADHD (Figure 2) . Preconception use of antidepressants was significantly associated with an increased risk of ADHD in children (HR 1.82; 95% CI 1.54-2.15). No significant heterogeneity was detected among the studies (I 2 = 0%). Furthermore, we found a significant association between preconception use of SSRIs and ADHD risk (HR 1.6; 95% CI 1.32-1.93; Figure S4 ), with no significant heterogeneity among studies (I 2 = 44.7%). Two studies 23, 25 compared the risk of ADHD in the children of women who used antidepressants during pregnancy with that in children of women who used antidepressants before conception ( Figure S5 ). The combined HR for ADHD risk was 0.9 (95% CI 0.72-1.12).
Risk of ADHD in the children of mothers with psychiatric disorders according to antidepressant exposure during pregnancy Two studies 22, 23 compared the risk of ADHD in the children of mothers with psychiatric disorders who were and were not exposed to antidepressants in utero ( Figure 3A) . The combined HR for ADHD risk was 0.96 (95% CI 0.76-1.2).
However, we found a significant association between maternal psychiatric disorders without antidepressant exposure and the risk of ADHD in offspring when compared Figure 3B ).
Three studies 21, 25, 26 conducted a sibling-matched analysis to control for confounding genetic and social factors. We found no statistically significant difference in the risk of ADHD between siblings who were or were not exposed to antidepressants in utero (HR 0.88, 95% CI 0.7-1.11; Figure 3C ).
Discussion
Main findings
Our meta-analysis of six cohort studies suggested that antidepressant exposure during pregnancy is associated with an increased risk of ADHD in the offspring even when exposure is limited to the preconception period. However, the rates of ADHD in the offspring of mothers who used antidepressants during pregnancy did not differ significantly from those of mothers with untreated psychiatric conditions, suggesting that maternal psychiatric illness is an important determinant of the risk of ADHD associated with antidepressant use during pregnancy. As there was a small number of studies included our review, we can be less certain about these results.
Strengths and limitations
The strength of our meta-analysis lies in the exclusive use of cohort studies, which are less prone to bias in terms of assessing exposures during pregnancy. Furthermore, we conducted additional analyses to control for confounding genetic factors and confounding by indication. Nonetheless, our review has some major limitations. The most important limitation of our meta-analysis is the small number of included studies, specifically when different analyses were used. Thus, our results of preconception exposure and maternal psychiatric status are limited by sample size and need further investigation.
A second limitation is the various definitions of assessment for ADHD used among studies. A prescription for ADHD medication was also used instead of diagnostic criteria to verify cases in three included studies. 21, 24, 25 Many children and adolescents with pervasive developmental disorder or autism spectrum disorder also exhibit some of the core symptoms of ADHD 27 ; the prevalence of treatment with ADHD medications among this population was increased in the past few years. 28 Only one 24 of these three studies excluded children with an autism spectrum diagnosis. Thus, different diagnostic definitions of ADHD may lead to substantially different assessments even in same study population. In addition, only two 22, 25 of the included studies restricted their sample to children who were at least 5 years old. Therefore, it is likely that the diagnoses were imprecise, as ADHD is generally diagnosed clinically in children aged 5 years or older. To investigate the association between antidepressant exposure during pregnancy and ADHD risk in the offspring, future research should comprise analyses based on an accurate definition of ADHD.
Thirdly, residual unknown confounders are always a concern in observational studies. Previous studies 29, 30 have reported that poor diet, alcoholism, smoking, drug use, and chronic conditions were more frequently seen in patients with psychiatric diseases than in those without psychiatric diseases, and therefore all of those factors could be considered potential risk factors for ADHD. However, these potential confounders were not consistent in each study. Future cohort studies should report analyses stratified by possible risk factors that fully adjust for potential confounders in order to rule out alternative explanations. Development of core outcome sets will aid the precise definition of essential outcomes and confounders.
Fourthly, the cohort studies are susceptible to detection bias because children who have been exposed to antidepressants may be more likely to receive more extensive assessment for developmental delays, which might lead to a higher rate in detection of ADHD. This bias may affect the true association.
Fifthly, the included studies were limited to cohort studies and published in English. Therefore, our results may potentially be susceptible to publication and language bias. Nonetheless, the included studies had generally satisfactory designs, methods, and outcomes, and all the included were of high quality. Finally, only one 26 included study used both a prescription database and self-report to verify maternal antidepressant use. Thus, the remaining studies could not ensure that the women recorded in the database actually took the prescribed drugs during pregnancy, which may have influenced our findings.
Interpretation
The association between antidepressant use during pregnancy and neurodevelopmental disorders in offspring has been a controversial topic for decades. In theory, antidepressant drugs can pass the placental barrier and directly affect brain development by altering neurotransmission. 31, 32 Several preclinical studies have shown that gestational exposure to antidepressants affects the development of neurotransmitter systems, resulting in long-lasting effects on the behaviour of offspring. 33, 34 However, animal studies are not always generalisable to the clinical situation. A previous meta-analysis 14 found a significantly increased risk of autism in children who were exposed to antidepressant drugs in utero. However, a more recent study 15 found that the statistical significance was lost when the authors pooled data adjusted for maternal psychiatric disorders, which supports our suggestion that the significant association between gestational exposure to antidepressant drugs and the risk of ADHD in offspring may be due to confounding by indication.
Attention-deficit/hyperactivity disorder has been shown to have a high heritability, estimated from twin studies to be between 70 and 80%. 8 Recent studies have shown that maternal psychiatric disorders are related to the development of ADHD in offspring 35 ; thus, investigation of the association between antidepressant use during pregnancy and ADHD in children should take maternal psychiatric conditions into consideration. In our overall analysis, antidepressant use during pregnancy was associated with ADHD when we used combined data adjusted for maternal psychiatric disorders. If a true causal association existed, the risk of ADHD would be greater for the children of mothers treated with antidepressants during pregnancy than for mothers with a psychiatric disorder who did not receive antidepressant treatment. However, the significant association between gestational exposure and ADHD risk disappeared when we pooled data from the sibling-matched studies, which partially controlled for confounding genetic factors. It should be noted, however, that the sample sizes in the sibling-matched studies were small. The ideal control for confounding by indication is a reference group of women with psychiatric disorders who did not take antidepressants during pregnancy. 36 Two studies 22, 23 directly compared the children of mothers with psychiatric conditions who were treated and those who were not treated with antidepressants during pregnancy and found that in utero exposure to antidepressants did not significantly increase the risk of ADHD. Furthermore, we found that maternal psychiatric illness itself is associated with the risk of ADHD in offspring, suggesting that confounding by indication may largely explain the observed association.
An unanticipated finding was that preconception antidepressant use was associated with an increased risk of ADHD in children. Most antidepressants are inactivated and eliminated within days to a week after use. Three of our included studies clearly defined preconception as 30 days prior to the estimated last menstrual period. Thus, it is unlikely that a carry-over effect can explain this finding, raising the question of whether confounding by indication may affect neurodevelopment and lead to ADHD. Consistent with our hypothesis, the risk of ADHD was not significantly different in children exposed to antidepressants during pregnancy and those whose mothers used antidepressants before conception.
These findings also bring up another possible cause of the confounding as the strong heritability of ADHD. 8 ADHD often persists into adulthood and is associated with high levels of depressive or anxious symptoms, but many adults with ADHD never receive a proper diagnosis or treatment. 37 It is possible that some of the mothers exposed to antidepressant included in these observational studies might have an undiagnosed ADHD. This may possibly explain why some studies, reported significant increases in the risk of ADHD with preconceptional exposure or maternal psychiatric diseases without exposure. In addition, the number of studies was very small, which limited the power of these analyses and the accuracy of our results.
Conclusions
The findings of our meta-analysis suggest that the link between prenatal antidepressant use and ADHD risk in children may be overestimated because previous epidemiological studies failed to control for maternal psychopathology as a confounding factor. Future studies using valid assessments of ADHD and maternal drug use during pregnancy that consider the severity of psychiatric illness during pregnancy are needed to clarify the contribution of maternal psychiatric status to the risk of ADHD in children.
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